Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Sumatriptan needle-free subcutaneous (Sumavel(®) DosePro™) approved for the acute treatment of migraine, with or without aura, and cluster headaches. Expert Rev Neurother 2011 Apr;11(4):481-90 PMID: 21469920

Pubmed ID

21469920

Abstract

Sumatriptan subcutaneous administration is the fastest and most effective of the triptans for relief of acute migraine headache. This occurs even when the patient has already developed symptoms related to central sensitization, a key parameter in determining the effectiveness of these agents. In patients whose migraine attacks have historically failed to respond to oral triptans, this route of administration has also proven to be more consistent and effective. Until recently this method of drug delivery was dependent upon a needle for administration. A new method of delivery for this agent, Sumavel(®) DosePro™, eliminates the needle and disposal issues coupled with an improved ease of use of drug delivery and acceptable tolerability for patients in clinical trials.

Author List

Freitag FG

Author

Frederick G. Freitag DO Associate Professor in the Neurology department at Medical College of Wisconsin




Scopus

2-s2.0-79953735515   7 Citations

MESH terms used to index this publication - Major topics in bold

Cluster Headache
Drug Administration Routes
Drug Delivery Systems
Female
Humans
Injections, Subcutaneous
Male
Migraine Disorders
Serotonin 5-HT1 Receptor Agonists
Sumatriptan
Treatment Outcome
jenkins-FCD Prod-296 4db9d02597e0a2e889e230f853b641c12f1c3ee3